急性骨髄性白血病(AML)-新分類・分子病態・治療-4.AML(APLを除く)の予後リスクと治療戦略

USUKI KENSUKE

Art

J-GLOBAL ID：201702239904560572 Reference number：17A0482320

急性骨髄性白血病(AML)-新分類・分子病態・治療-4.AML(APLを除く)の予後リスクと治療戦略

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=17A0482320&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0482320&from=J-GLOBAL&jstjournalNo=L1289A") }}

Author (1)：
Material：
Volume： 27 Issue： 4 Page： 519-530 Publication year： Mar. 30, 2017
JST Material Number： L1289A ISSN： 1344-6940 Document type： Article
Article type：解説 Country of issue： Japan (JPN) Language： JAPANESE (JA)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0482320&from=J-GLOBAL&jstjournalNo=L1289A") }}

Blood cell tumors(=neoplasms) , Treatment for tumors in general , Clinical application of antitumor(=antineoplastic)drugs

, , ,

, , , , , , , ,

Return to Previous Page